Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $9.40 Consensus Price Target from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have received a consensus rating of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $9.40.

Several brokerages have recently weighed in on RXRX. JPMorgan Chase & Co. raised Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their target price for the stock from $10.00 to $11.00 in a research note on Wednesday, December 17th. Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Wednesday, October 8th. Finally, UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th.

Insider Activity at Recursion Pharmaceuticals

In other news, Director Blake Borgeson sold 220,000 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $4.36, for a total value of $959,200.00. Following the transaction, the director directly owned 6,649,863 shares of the company’s stock, valued at approximately $28,993,402.68. This trade represents a 3.20% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Ben R. Taylor sold 21,383 shares of the company’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $4.18, for a total value of $89,380.94. Following the completion of the sale, the chief financial officer owned 761,550 shares of the company’s stock, valued at $3,183,279. This trade represents a 2.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 585,786 shares of company stock valued at $2,558,598. 8.43% of the stock is owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors have recently bought and sold shares of RXRX. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Recursion Pharmaceuticals by 183.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,408,524 shares of the company’s stock valued at $33,901,000 after purchasing an additional 4,149,346 shares in the last quarter. Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the 2nd quarter worth approximately $16,040,000. Bank Pictet & Cie Europe AG purchased a new stake in shares of Recursion Pharmaceuticals during the 3rd quarter worth approximately $7,954,000. Stratos Wealth Partners LTD. boosted its holdings in shares of Recursion Pharmaceuticals by 724.3% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 98,704 shares of the company’s stock valued at $499,000 after buying an additional 86,730 shares in the last quarter. Finally, Ethic Inc. purchased a new position in shares of Recursion Pharmaceuticals in the 2nd quarter valued at $107,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $4.69 on Friday. The firm has a market capitalization of $2.44 billion, a P/E ratio of -2.61 and a beta of 0.95. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The stock has a 50-day simple moving average of $4.44 and a two-hundred day simple moving average of $5.05. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.02. Recursion Pharmaceuticals had a negative return on equity of 72.74% and a negative net margin of 1,637.81%.The business had revenue of $5.18 million for the quarter, compared to analyst estimates of $19.36 million. During the same quarter in the prior year, the firm posted ($0.34) EPS. The business’s quarterly revenue was down 80.1% compared to the same quarter last year. On average, equities analysts forecast that Recursion Pharmaceuticals will post -1.57 earnings per share for the current year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.